Send to

Choose Destination
Curr Hematol Rep. 2005 Jan;4(1):51-8.

C-kit as a target in the treatment of acute myelogenous leukemia.

Author information

Department of Hematology Medical Oncology, Desk 35, The Cleveland Clinic Lerner College of Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA.


Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are currently being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of de novo AMLs and 95% of relapsed AMLs. C-kit mediates proliferation and anti-apoptotic effects in AML. This review will discuss the biology of c-kit in normal and malignant hematopoiesis, and the recent clinical trials targeting c-kit in AML.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center